Conclusions: These successful results for EGFR-targeting inhalable immunoliposomes exhibited potential for contributing to greater anti-tumor efficacy for the treatment of non-small cell lung cancer. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.